Addition of Atrasentan to Renin-Angiotensin System Blockade Reduces Albuminuria in Diabetic Nephropathy
- 1 April 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Society of Nephrology
- Vol. 22 (4), 763-772
- https://doi.org/10.1681/asn.2010080869
Abstract
Although endothelin-receptor antagonists reduce albuminuria in diabetic nephropathy, fluid retention limits their use. Here, we examined the effect of atrasentan, a selective endothelin A receptor (ETAR) antagonist, on albuminuria in a randomized, double-blind, placebo-controlled trial of subjects with diabetic nephropathy already receiving stable doses of renin-angiotensin system (RAS) inhibitors. We randomly assigned 89 subjects with eGFR >20 ml/min per 1.73 m2 and a urinary albumin-to-creatinine ratio (UACR) of 100 to 3000 mg/g to placebo or atrasentan (0.25, 0.75, or 1.75 mg daily) for 8 weeks. Compared with placebo, atrasentan significantly reduced UACR only in the 0.75- and 1.75-mg groups (P = 0.001 and P = 0.011, respectively). Compared with the 11% reduction in the geometric mean of the UACR from baseline to final observation in the placebo group during the study, the geometric mean of UACR decreased by 21, 42, and 35% in the 0.25-, 0.75-, and 1.75-mg atrasentan groups (P = 0.291, P = 0.023, and P = 0.073, respectively). In the placebo group, 17% of subjects achieved ≥40% reduction in UACR from baseline compared with 30, 50, and 38% in the 0.25-, 0.75-, and 1.75-mg atrasentan groups, respectively (P = 0.029 for 0.75 mg versus placebo). Peripheral edema occurred in 9% of subjects receiving placebo and in 14, 18, and 46% of those receiving 0.25, 0.5, and 1.75 mg atrasentan, respectively (P = 0.007 for 1.75 mg versus placebo). In summary, atrasentan, at the doses tested, is generally safe and effective in reducing residual albuminuria and may ultimately improve renal outcomes in patients with type 2 diabetic nephropathy.Keywords
This publication has 27 references indexed in Scilit:
- Avosentan for Overt Diabetic NephropathyJournal of the American Society of Nephrology, 2010
- Endothelin, hypertension and chronic kidney disease: new insightsCurrent Opinion in Nephrology and Hypertension, 2010
- Avosentan Reduces Albumin Excretion in Diabetics with MacroalbuminuriaJournal of the American Society of Nephrology, 2009
- Efficacy and Safety of Atrasentan in Patients With Cardiovascular Risk and Early AtherosclerosisHypertension, 2008
- Effect of a Multifactorial Intervention on Mortality in Type 2 DiabetesNew England Journal of Medicine, 2008
- Endothelin A Receptor Blockade Reduces Diabetic Renal Injury via an Anti-Inflammatory MechanismJournal of the American Society of Nephrology, 2007
- Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retentionAmerican Journal of Physiology-Renal Physiology, 2006
- Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetesJCI Insight, 2006
- Collecting duct-specific knockout of the endothelin A receptor alters renal vasopressin responsiveness, but not sodium excretion or blood pressureAmerican Journal of Physiology-Renal Physiology, 2005
- Effect of Compensated Renal Dysfunction on Approved Heart Failure MarkersHypertension, 2005